Xiaolin Wang, Sc.D.

Xiaolin Wang, Sc.D.

Executive Vice President, DevelopmentatRevolution Medicines· In proxies 2021–2024

Pay in FY2023+80% from the year before · Revolution Medicines stock +20.4% the same year

Xiaolin Wang, Sc.D. was paid $3.2M in FY2023 (Dec), up 80%. Revolution Medicines stock rose 20.4% that year.

Pay$100 in the stock at the end of FY20 → $72
Pay is from the Summary Compensation Table of each Revolution Medicines proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Revolution MedicinesPublic company · 5 yr
    • Executive Vice President, Development2021 – Present · 5 yrStock in role +343%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?